Panelists discuss how various patient characteristics, including age, fitness level, cytogenetic risk, and comorbidities, influence their decision to use more intensive quadruplet regimens like D-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone) vs standard triplet regimens, such as VRd or KRd (carfilzomib, lenalidomide, and dexamethasone) in transplant-eligible multiple myeloma patients, while also considering administration logistics and supportive care requirements
Panelists discuss how transplant eligibility significantly influences first-line treatment goals and initial therapy selection in multiple myeloma, often leading to more intensive induction regimens aimed at achieving deep remissions.
Panelists discuss how their institutions approach frontline treatment for transplant-eligible multiple myeloma patients, typically using a combination of novel agents like proteasome inhibitors and immunomodulatory drugs, followed by autologous stem cell transplantation and maintenance therapy, while considering factors such as patient characteristics and treatment response to guide therapy sequencing.
Panelists discuss how the current first-line treatment options for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) typically involve combination therapies including proteasome inhibitors, immunomodulatory drugs, and steroids.
Pharmacists play a vital role in therapy selection.
The significant surge in oncology drug shortages in 2023 particularly affected essential chemotherapeutic drugs.
Treatment options are distinct in their mechanisms, safety profiles, and implications for patients’ quality of life.
Ph-like ALL may be predominantly prevalent in Hispanic and Latino populations.
In crafting a patient-centered regimen, the convergence of expertise from physicians and pharmacists, paired with the values and preferences of patients, becomes paramount.
A single-center experience at a tertiary medical center precision medicine clinic provides insight.
Achieving MRD flow cytometry negativity is crucial in monitoring and predicting survival outcomes.
Substantial strides have been made in the management of Ph+ ALL.
The role of monoclonal antibodies in minimizing COVID-19–related complications remains important to assess.
A retrospective analysis presents unique results for AML treatment.
